← All candidates
One insider buy in the last year — $104.9K in all.
47 filings on record.
MNPRMonopar Therapeutics
NasdaqCM · Healthcare · $700.28M
$104.33
-3.68% · Sep 15
One insider buy in the last year — $104.9K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 14 sells◆ 7 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what MNPR ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$700.28M
Float
4.5M
67% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Financial Officer
Vu Quan Anh
Bought $104.9K on Dec 26 — 1,500 sh @ $69.95, held direct, 100% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
42 more transactions on Pro →The file stays open
47 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice